FDA recommends pre-BLA meeting for Rezolute's congenital HI drug

October 5, 2026 7:00 AM

Rezolute, Inc. (Nasdaq: RZLT) announced that the U.S. Food and Drug Administration has recommended a pre-biologics license application (BLA) meeting ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found